Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 inhibitor  GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases...

Related Keywords

Japan ,Belgium ,Mechelen ,Region Flamande ,Daniele Dambrosio ,Marieke Vermeersch ,Sandra Cauwenberghs ,Van Gijsel ,British Isles Lupus Assessment Group ,Linkedin ,Exchange Commission ,Twitter ,Composite Lupus Assessment ,Cutaneous Lupus Erythematosus Disease Area ,Severity Index Activity ,Lupus Low Disease Activity State ,Danieled Ambrosio ,Therapeutic Area Head Immunology ,Markets ,